Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
Hand osteoarthritis (HOA) which affects the interphalangeal joints and the
metacarpophalangeal of the thumb is a common disease, the prevalence of which being about 30
% of the population over than 70. Some forms of HOA are refractory to usual treatments
(analgesics, NSAIDs, local injections) and can lead to a high disability. In vitro and in
vivo studies showed that IL-6 is involved in the OA process. The aim of the present study is
to assess the efficacy of an Interleukin-6-Receptor Inhibitor (tocilizumab) on pain and
function in patients with refractory hand OA.